Company intelligence / Profile preview

Alligator Bioscience AB

Lund, Sweden

Ownership: Public · ATORX
Employees: ~46
Development stage: Phase 2

Overview

Mitazalimab (lead asset) showed promising results in OPTIMIZE-1 Phase 2 trial for pancreatic cancer with 29.4% survival rate at 24 months, which is three times higher than chemotherapy alone. The company is preparing for Phase 3 initiation in H1 2025.

Therapeutic areas: Oncology
Modalities: Antibody-based pharmaceuticalsMonoclonal antibodiesBispecific antibodiesAgonistic mono- and bispecific antibodies
Industry: Biotech

Drug pipeline

7 assets

mitazalimab

6 more assets in the full pipeline.

Request access →

Partnerships

Shanghai Henlius Biotech Inc.Aptevo Therapeutics Inc.MacroGenics Inc.Orion CorporationBiotheus Inc.Abclon Inc.BioArctic AB

Financials

Market cap: $2.3M
Total revenue: $102.8M
Enterprise value: $30.3M

Beyond the preview

Go deeper on Alligator Bioscience AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alligator Bioscience AB.

Explore the full profile